FDA grants AZ's Imfinzi fast review in new lung cancer use

The FDA has granted AstraZeneca’s Imfinzi immunotherapy a faster six-month review in patients with extensive-stage small cell lung cancer.

Merck & Co's Keytruda shows promise with prostate cancer 'su...

A small proportion of men with advanced prostate cancer, who have exhausted all other treatment options, were ‘super responders’ to Merck & Co’s Keytruda (pembrolizumab) immunotherapy i

NICE backs Ibrance for breast cancer via Cancer Drugs Fund

Blackstone and Ferring pump $570m into bladder cancer gene t...

Switzerland’s Ferring Pharmaceuticals has joined with US investor Blackstone Life Sciences to pump $570 million into a bladder cancer gene therapy project.

Takeda sets sights on first-line lung cancer market with new...

Brisk trade in risky three-drug 'bet' option after BMS/Celge...

Bristol-Myers Squibb’s $74 billion merger with Celgene went ahead this week after clearance from US competition regulators, and the focus has shifted on to whether Celgene shareholders will